Genzyme may delay production plans for Myozyme


NEW YORK Genzyme said Wednesday that its plans to boost production of the drug Myozyme face possible delays, causing its shares to fall 4.3 percent despite increases in profits.

Myozyme, known generically as alglucosidase alfa, is used to treat Pompe disease, a genetic illness that impairs muscles.

Genzyme launched Myozyme in 2006, and it has since been approved in 36 countries.

This ad will auto-close in 10 seconds